Main menu


The US Drug Administration is reviewing a new drug to treat asthma that reduces attacks

Both AstraZeneca and Amgen said they had received a rapid review from the US Food and Drug Administration (FDA) for their asthma treatment.

Pharmaceutical company AstraZeneca and Amgen Inc. said Thursday that their experimental drug, Tezepelumab, has received rapid review by the U.S. Food and Drug Administration for approval as a treatment for asthma.

According to Reuters, the drug has shown in trials that it can reduce asthma attacks in patients with severe and uncontrolled forms of respiratory disease, with the promise of its wider use against various etiologies.

"Acute asthma is a challenging and complex disease for clinicians and millions of patients and has high unmet medical needs," said David Rees, Amgen's chief executive officer.

He added, approximately 339 million people suffer from asthma worldwide, 10 percent of whom suffer from severe forms of the condition.

AstraZeneca said the rapid review is following its request to the US regulator, and a decision on the drug is expected in the first quarter of next year.

She added that tizpilumab reduced the rate of asthma attacks by 56 percent among patients compared to placebo in a last-stage, one-year study of nearly 1,000 patients already receiving standard care.

Detailed data, presented at a virtual meeting of the American Academy of Allergy, Asthma and Immunology, showed that the drug reduced the risk of seizures by 70% in patients.

Asthma attacks occur as a result of swelling and narrowing of the airways, which can exacerbate asthma attacks. Many factors can cause the respiratory condition to become severe.

According to AstraZeneca's website, tezepelumab works by blocking a type of immune protein called TSLP, which is found in the linings of the lungs. This protein called TSLP belongs to a group of cytokines responsible for alarming the body's immune system and can also trigger inflammation.